

Prescribers Guide: TPP SystemOne

FDB OptimiseRx is fully integrated into the prescribing workflow within TPP SystemOne. OptimiseRx uses the medication prescribed and relevant patient specific criteria based on coding within the patient record (such as demographics, medication history, clinical conditions and lab results) to determine whether an OptimiseRx message should present to the prescriber at the point of care.

OptimiseRx messages appear for relevant patients when:

- initiating medication(s) for the first time
- reauthorising repeat medication(s)
- re-prescribing past medication(s)
- using the FDB button

Messages usually present at the start of the prescribing workflow, upon drug selection, to provide advice on local formulary status, best practice guidance or cost-effective prescribing based on local and national recommendations.

Simple cost swaps offering cheaper alternatives may also present at the end of the prescribing workflow after completion of dose and quantity information.

Where possible, messages will offer alternative products which prescribers can select in place of the original. Other messages may advise the medication is not recommended for that patient or offer relevant prescribing information (e.g. monitoring advice).

Best Practice and Cost Saving messages with multiple Alternative Products

Headline message for quick reference

Click this box to accept message and reveal the Alternative Products (see Pg 2)

Click Overrule or Overrule with Reason to reject the message and proceed with the original selection (see also Pg 3)

Click here to see the attributes in the patient record which led to the message being presented.

Click on the hyperlinks for direct access

The options to Proceed with the Alternative Product or Original Medications are enabled once the messages have been acknowledged by the Overrule or Show Suggestions buttons above

Accepting a message takes two steps; click to view the locally approved Alternative Products and then select which of these to prescribe.

OptimiseRx Warnings for Omeprazole 20mg dispersible gastro-resistant tablets

Expand All Collapse All Reset All Warnings Override All with Reason Override All

Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective

Show 2 Suggestions Override with Reason Override

Clicking Show Suggestions opens the dialog box below

Suggested Medication

Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective

• Dispersible and orodispersible tablets should be reserved for patients with swallowing difficulties. The product literature for Losec MUPS dispersible tablets states that both omeprazole formulations are bioequivalent. Based on treatment doses of the two agents as detailed in their product literature, for most conditions (excluding Zollinger-Ellison syndrome and other hypersecretory conditions), omeprazole 20mg may be considered equivalent to lansoprazole 30mg; dose adjustment may be necessary depending on the specific condition being treated and patient response. Lansoprazole is not licensed for patients aged under 18 years.

References [electronic Medicines Compendium](#) [electronic Medicines Compendium](#) [electronic Medicines Compendium](#)

[Why is this warning showing?](#)

Suggested Products

Hide 1 drugs with warnings

Product	Warnings
lansoprazole 30mg orodispersible gastro-resistant tablet	INTERACTION: Interaction found between omeprazole 20mg gastro-resistant capsules and erythromycin stearate 500mg tablets: Omeprazole/esomeprazole plasma level may be increased/risk of arrhythmias

Ok Cancel

List of Alternatives Products

1. Click on the chosen Alternative Product
2. Click OK

NB If SystemOne has identified patient specific warnings (e.g. drug-drug interactions and patient sensitivities) for any of the alternatives offered, these may appear greyed out with details of the relevant warning. Prescribers have the option to hide these options from view by clicking on the tick-box titled 'Hide drugs with warnings'.

To Reject a Message

Providing feedback on the rejection of a message is optional. Any reasons entered will be made available in a report which the ICB/LHB Medicines Optimisation Team can use to assist in managing the configuration of OptimiseRx. FDB will also review these reasons and use them to support message review and updates.

If multiple messages appear in the dialog box, they can be rejected as a group.

OptimiseRx Warnings for Omeprazole 20mg dispersible gastro-resistant tablets

▼ Expand All ▶ Collapse All 🔄 Reset All Warnings ❌ Override All with Reason ❌ Override All

Prescribing omeprazole 20mg gastro-resistant capsules (or orodispersible lansoprazole if dysphagic) instead of omeprazole 20mg dispersible tablets is more cost-effective ✓ Show 2 Suggestions ❌ Override with Reason ❌ Override

• Dispersible and orodispersible tablets should be reserved for patients with swallowing difficulties. The product literature for Losec MUPS dispersible tablets states that both omeprazole formulations are bioequivalent. Based on treatment doses of the two agents as detailed in their product literature, for most conditions (excluding Zollinger-Ellison syndrome and other hypersecretory conditions), omeprazole 20mg may be considered equivalent to lansoprazole 30mg; dose adjustment may be necessary depending on the specific condition being treated and patient response. Lansoprazole is not licensed for patients aged under 18 years.

References [electronic Medicines Compendium](#) [electronic Medicines Compendium](#) [electronic Medicines Compendium](#)

[Why is this warning showing?](#)

Use 'Override with Reason' to provide feedback when rejecting a message

Click on Override to reject message without giving a reason

❌ Override with Reason ❌ Override

- Disagree with rule
- Not suitable for this patient
- Data missing from patient record
- Initiated by specialist
- Temporary resident
- Tests Complete, not recorded in SystemOne
- Other Reason

Users can select from a pre-defined list or enter free text by selecting 'Other Reason' from the dropdown and typing feedback in the box provided

Override Reason

Enter a reason for overruling Enter text here

Ok Cancel

Simple Cost Saving Messages

Simple cost swap messages will appear after entering the quantity and dosage information, as this data is used to identify savings opportunities. If available, a cheaper alternative will be shown.

OptimiseRx Cost Savings for Omeprazole 20mg gastro-resistant tablets

Original	Suggested
Omeprazole 20mg gastro-resistant tablets 28 tablets Generic £5.94	Omeprazole 20mg gastro-resistant capsules 28 capsules Generic £0.88

Total saving £5.06

Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Use Original Use Alternative Cancel

Continues prescribing the original medication

Replaces the original drug with the alternative in the prescribing screen.

Returns to the medication screen.

To Acknowledge an Information Message

OptimiseRx Warnings for Metformin 500mg tablets

Expand All Collapse All

Monitor serum creatinine; no evidence of monitoring found within 13 months

- An RCGP prescribing safety indicator (2014) states that prescribing metformin without appropriate monitoring is potentially harmful; due to the renal elimination of metformin and potential for adverse effects with increased plasma levels, renal function should be monitored before initiating therapy and regularly (e.g. annually) thereafter.

References bjgp.org

[Why is this warning showing?](#)


Disclaimer: The OptimiseRx module is intended for the use of healthcare professionals and provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance [View Full Disclaimer](#)

Proceed

The Best Practice guidance in an Information message can be acknowledged by clicking Proceed.

RAG / Formulary Message

The local organisation can configure whether a message appears with a red or amber banner; red usually indicates that a product shouldn't be prescribed, and amber is often reserved for medications that are subject to shared care arrangements.



↑ To 'accept' the advice of a red/do not prescribe message, click on Proceed to acknowledge then delete drug from prescribed drug field

FDB Button

While in a patient record, this bespoke OptimiseRx feature can be used to **review a patient's repeat medications or conduct a medicines review outside of the prescribing workflow**. To do this, the FDB button must be added to the toolbar. Depending on local setup, the ability to customise toolbars may be managed centrally or individually by users.

To configure the OptimiseRx button in SystmOne:

- Right-click on the toolbar and select Configure Toolbar
- Select the toolbar you wish to add the button to and click Amend Button Set
- Either Type "OptimiseRx" into the Search field and click Search or open the prescribing folder on tile left hand side tree and select fdb OptimiseRx
- Double-click on the 'fdb OptimiseRx' option in the tree to move it into the right-hand pane
- Click OK on the Toolbar Configuration dialogue

Using the FDB (OptimiseRx) Button:

OptimiseRx can be run against any given patient outside of the prescribing workflow to:

- Identify opportunities for optimising current prescriptions
- Support medicines usage review
- Analyse complex multi-morbidity and polypharmacy patients

Clicking on the FDB button will display a selection of relevant messages that are suitable for presentation such as best practice recommendations, monitoring advice and cost-effective alternatives. Note that formulary messages do not display in this view.

